Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 6
Submit an article Journal homepage
486
Views
15
CrossRef citations to date
0
Altmetric
Review

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer

Niki KarachaliouInstitute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, SpainView further author information
,
Mariacarmela SantarpiaMedical Oncology Unit, Department of Human Pathology ‘G. Barresi,’University of Messina, Messina, ItalyView further author information
,
Maria Gonzalez CaoInstitute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, SpainView further author information
,
Cristina TeixidoPangaea Oncology, Quirón-Dexeus University Institute, Barcelona, SpainView further author information
,
Aaron E. SosaInstitute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, SpainView further author information
,
Jordi BerenguerPangaea Oncology, Quirón-Dexeus University Institute, Barcelona, SpainView further author information
,
Alejandra Rodriguez CapoteMedical Oncology Department, University Hospital of Canary Islands, Tenerife, SpainView further author information
,
Giuseppe AltavillaMedical Oncology Unit, Department of Human Pathology ‘G. Barresi,’University of Messina, Messina, ItalyView further author information
&
Rafael RosellGermans Trias i Pujol Research Institute, Badalona, Spain;Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, SpainCorrespondence[email protected]
View further author information
 show all
Pages 713-722 | Received 03 Mar 2017, Accepted 25 Apr 2017, Published online: 18 May 2017

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Bin Yao, Xue Han, Linrong Pang, Caihong Xu, Sisi Liu, Xiaochun Cheng & Jun Chen. (2021) Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report. OncoTargets and Therapy 14, pages 4329-4333.
Read now
Ali S Abdelhameed, Mohamed W Attwa & Adnan A Kadi. (2020) Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach. Drug Design, Development and Therapy 14, pages 5259-5273.
Read now

Articles from other publishers (13)

Qi Song, Jie Li, Qi Xiong, Ya Ping Long, Bo Yang, Zhou Huan Dong, Chao Yang Liang & Bo Yang. (2023) Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK -positive non-small-cell lung cancer . Immunotherapy 15:11, pages 809-817.
Crossref
Yanchun Zhang, Xuexue Xiong, Renhong Sun, Xiaotong Zhu, Chen Wang, Biao Jiang, Xiaobao Yang, Dake Li & Gaofeng Fan. (2023) Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness. Journal of Biological Chemistry 299:6, pages 104825.
Crossref
Jiajia Wu & Zhenghong Lin. (2022) Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. International Journal of Molecular Sciences 23:23, pages 15056.
Crossref
Junfei Feng, Jing Leng, Changdi Zhao, Jie Guo, Yongbing Chen & Haifeng Li. (2022) High expression of 14‑3‑3ơ indicates poor prognosis and progression of lung adenocarcinoma. Oncology Letters 24:1.
Crossref
Zhen Li, Fang Liu, Shuang Wu, Shi Ding, Ye Chen & Ju Liu. (2022) Research Progress on the Drug Resistance of ALK Kinase Inhibitors. Current Medicinal Chemistry 29:14, pages 2456-2475.
Crossref
Cheng-Yu Jin, Liang Du, A-Han Nuerlan, Xiao-Lei Wang, Yong-Wei Yang & Rui Guo. (2020) High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging 13:3, pages 3518-3535.
Crossref
Jie Luo & Xiaotian Du. (2021) A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes. Medicine 100:50, pages e28237.
Crossref
Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li & Tingjun Hou. (2019) Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry 62:24, pages 10927-10954.
Crossref
Maximilian Hochmair, Christoph Weinlinger, Sophia Schwab, Jakob Naber, Ulrike Setinek, Dagmar Krenbek, Matthias H. Urban, Hannah Fabikan, Stefan Watzka, Renate Koger, Andreas Fazekas, Erwin Bitterlich, Arschang Valipour & Otto C. Burghuber. (2019) Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines. Anti-Cancer Drugs 30:7, pages 740-744.
Crossref
Meijuan Ding, Lili Deng, Ruoying Yu, Dan Lu, Yun Bai, Xue Wu, Yang W. Shao & Yu Yang. (2019) Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy. Clinical Lung Cancer 20:3, pages e229-e232.
Crossref
Dimple R. Bhatia, Sushmita Rath & Sudeep Gupta. 2019. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach 539 583 .
Marco Wachtel & Beat W. Schäfer. (2018) PAX3-FOXO1: Zooming in on an “undruggable” target. Seminars in Cancer Biology 50, pages 115-123.
Crossref
L. Gust, G. Brioude, N. Ghourchidian, S. Dizier, A. Charvet, D. Trousse, X.B. D’journo, C. Doddoli, M. Leone & P.-A. Thomas. (2017) Stratégie chirurgicale : quelles nouvelles techniques ? La chirurgie minimalement invasive (RATS/VATS). Les exérèses d’épargne parenchymateuse. Les parcours de soin accélérés. Revue des Maladies Respiratoires Actualités 9:2, pages 161-171.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.